Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - BLA/NDA/ANDA
FDA Panel Unanimously Backs Novartis AG (NVS)' Psoriasis Drug 10/20/2014 3:34:36 PM
Eisai Inc. (ESALF.PK) Announces FDA Acceptance Of Supplemental New Drug Application For Antiepileptic Drug Perampanel As Adjunctive Treatment Of Primary Generalized Tonic-Clonic Seizures 10/20/2014 9:02:51 AM
Pharmacyclics, Inc. (PCYC) Files Supplemental New Drug Application For IMBRUVICA® For Waldenstrom's Macroglobulinemia 10/20/2014 8:29:51 AM
FDA Accepts For Review A Biologics License Application For Merck & Co. (MRK) And Sanofi Pasteur (SASY.PA)’s Investigational Pediatric Hexavalent Vaccine 10/20/2014 7:51:47 AM
Janssen Research & Development Release: IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted To The U.S. FDA For Waldenstrom's Macroglobulinemia 10/20/2014 7:23:33 AM
Matinas BioPharma Submits Investigational New Drug Application For Lead Product Candidate MAT9001 For The Treatment Of Severe Hypertriglyceridemia 10/20/2014 6:17:27 AM
Novartis AG (NVS) Psoriasis Drug Secukinumab Benefits Outweighs Risk: FDA Staff 10/17/2014 5:55:48 AM
Repros Therapeutics Inc. (RPRX) Shares Tank On Drug Application Setback 10/17/2014 7:15:39 AM
Actavis (ACT) Confirms Generic Quillivant XR® Patent Challenge 10/16/2014 7:58:01 AM
AstraZeneca PLC (AZN) Holds Its Breath As European Regulators Mull Cancer Drug Fate 10/15/2014 6:34:25 AM
Alexion Pharmaceuticals Inc. (ALXN) Submits NDA In Japan For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 10/15/2014 11:02:03 AM
FDA Grants Eisai Company, Ltd. (ESALY.PK)'s Investigational Agent Lenvatinib Priority Review Designation For The Treatment Of Advanced Thyroid Cancer 10/15/2014 8:04:28 AM
Pfizer (PFE)'s Palbociclib Granted FDA Priority Review 10/13/2014 8:30:33 AM
Supernus Pharmaceuticals (SUPN) Announces Paragraph IV ANDA Filing For Trokendi XR(R) 10/14/2014 8:22:17 AM
ProSensa Holding N.V. (RNA) Begins NDA Submission To The FDA For Exon-Skipping Drug Drisapersen To Treat Duchenne Muscular Dystrophy 10/13/2014 7:33:04 AM
1234567
//-->